Navigation Links
China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits

BEIJING, Nov. 20 /PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it has successfully completed the development of two proprietary molecular diagnostic kits for the detection of epidermal growth factor receptor ("EGFR") abnormalities in patients with non-small cell lung cancer ("NSCLC"). The Company expects to offer the kits to its hospital customers through its direct sales force in January 2009.

Currently, Iressa and Tarceva are commonly used drugs for the treatment of patients with NSCLC. These drugs target the EGFR gene located at 7p12. According to publications in medical journals, EGFR abnormalities have been found in approximately 85% of NSCLC patients responsive to Iressa and Tarceva. Some of these abnormalities could be identified by using FISH-based technique to detect increase in gene copy numbers; others could be detected by using real-time PCR-based technique to analyze EGFR gene mutations. The Company has successfully completed the development of both FISH and real-time PCR-based molecular diagnostic kits for detecting EGFR abnormalities. The test result provides guidance for physicians to determine the most appropriate therapy for patients with NSCLC.

"We are excited about the successful development of molecular diagnostic kits for non-small cell lung cancer therapy," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "We will continue to leverage our molecular diagnostic technology platforms to develop more products with significant market potential."

Lung cancer is one of the most common cancers in the world and it is the leading cause of cancer death in China. It is estimated that more than 500,000 new lung cancer cases were diagnosed each year in China and the incidence rate of lung cancer is expected to continue to increase.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit .

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833

SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
4. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
5. China Biologic Products Announces Third Quarter 2008 Results Conference Call
6. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
7. China Clean Energy Resumes Biodiesel Production After Temporary Halt
8. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):